3-12584929-T-C
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 3P and 5B. PM1PP2BP6BS2
The NM_002880.4(RAF1):āc.1721A>Gā(p.Tyr574Cys) variant causes a missense change. The variant allele was found at a frequency of 0.000139 in 1,614,072 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002880.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000125 AC: 19AN: 152196Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000179 AC: 45AN: 251334Hom.: 0 AF XY: 0.000221 AC XY: 30AN XY: 135832
GnomAD4 exome AF: 0.000141 AC: 206AN: 1461876Hom.: 0 Cov.: 32 AF XY: 0.000154 AC XY: 112AN XY: 727238
GnomAD4 genome AF: 0.000125 AC: 19AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.000175 AC XY: 13AN XY: 74340
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:2
This variant is associated with the following publications: (PMID: 27050224, 29522511) -
- -
RAF1: PP3, BS2 -
not specified Uncertain:1Benign:1
Variant summary: RAF1 c.1721A>G (p.Tyr574Cys) results in a non-conservative amino acid change located in the Protein kinase domain (IPR000719) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00018 in 251334 control chromosomes, predominantly at a frequency of 0.00029 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 11.6 fold of the estimated maximal expected allele frequency for a pathogenic variant in RAF1 causing Noonan Syndrome And Related Conditions phenotype (2.5e-05). c.1721A>G has been reported in the literature in individuals affected with core-binding factor acute myeloid leukemia (Zhang_2015), Idiopathic cytopenia of undetermined significance (Molteni_2023), and prostate cancer (Liang_2022). These reports do not provide unequivocal conclusions about association of the variant with Noonan Syndrome And Related Conditions. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. ClinVar contains an entry for this variant (Variation ID: 177842). One ClinVar submission reports the variant to co-occur with a likely pathogenic PTPN11 variant in two affected individuals in a family (variant was not specified), in addition, it also reports the variant of interest in an unaffected parent; these data provide supporting evidence for a benign role. The following publications have been ascertained in the context of this evaluation (PMID: 26580448, 37216690, 36095024). Based on the evidence outlined above, the variant was classified as likely benign. -
Variant classified as Uncertain Significance - Favor Benign. The p.Tyr574Cys var iant in RAF1 has been identified by our laboratory in 3 individuals with clinica l features of Noonan syndrome and in two of these cases it was inherited from a parent. The first individual inherited it from an unaffected parent. The second inherited it from a mildly affected parent; however, both the proband and mildly affected parent carried an additional likely pathogenic variant in PTPN11 sugge sting that the p.Tyr574Cys variant may not be the cause of their phenotype (LMM Data). This variant has been identified in 20/66732 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs3702 42565). Computational prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. In summary, while the cl inical significance of the p.Tyr574Cys variant is uncertain, these data suggest that it is more likely to be benign. -
Noonan syndrome 5 Uncertain:1Benign:1
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as likely benign. Following criteria are met: 0103 - Loss of function and gain of function are known mechanisms of disease in this gene. Gain of function associated with Noonan (MIM#611553) and LEOPARD syndromes (MIM#2611554) with HCM, while loss of function associated non-HCM-associated variants (PMID: 17603483, 17603482). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from tyrosine to cysteine. (I) 0251 - This variant is heterozygous. (I) 0308 - Population frequency for this variant is out of keeping with known incidence of Noonan syndrome (MIM#611553). (SB) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated kinase domain (PDB). (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0808 - Previous reports of pathogenicity for this variant are conflicting. This variant has been classified both as a VUS and likely benign by diagnostic laboratories in Clinvar (ClinVar). (I) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. -
LEOPARD syndrome 2;C1969057:Noonan syndrome 5;C4014656:Dilated cardiomyopathy 1NN Uncertain:1
- -
Noonan syndrome Uncertain:1
The RAF1 c.1721A>G (p.Tyr574Cys) missense change has a maximum subpopulation frequency of 0.029% in gnomAD v2.1.1 (BS1; https://gnomad.broadinstitute.org/variant/3-12626428-T-C). This variant occurs in a gene where missense variants are more likely to be damaging based on methods described by Lek et al. (PP2; PMID: 27535533). Five of seven in silico tools predict a deleterious effect of this variant on protein function (PP3), but to our knowledge these predictions have not been confirmed by functional assays. To our knowledge, this variant has not been reported in individuals with RASopathy conditions. In summary, this variant meets criteria to be classified as of uncertain significance based on the ACMG/AMP criteria, as specified by the RASopathy Variant Curation Expert Panel (PMID:29493581): BS1, PP2, PP3. -
Primary familial hypertrophic cardiomyopathy Uncertain:1
- -
Cardiovascular phenotype Uncertain:1
The p.Y574C variant (also known as c.1721A>G), located in coding exon 15 of the RAF1 gene, results from an A to G substitution at nucleotide position 1721. The tyrosine at codon 574 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant was reported in exome findings from a superior coloboma cohort; however, clinical details were limited (Hocking JC et al. PLoS Genet., 2018 03;14:e1007246). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. -
RASopathy Uncertain:1
This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 574 of the RAF1 protein (p.Tyr574Cys). This variant is present in population databases (rs370242565, gnomAD 0.03%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with RAF1-related conditions. ClinVar contains an entry for this variant (Variation ID: 177842). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is not expected to disrupt RAF1 function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
LEOPARD syndrome 2 Benign:1
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
Hereditary cancer Benign:1
This variant is considered likely benign or benign based on one or more of the following: it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease, and/or has normal protein function, and/or has lack of segregation with disease, and/or has been detected in co-occurrence with known pathogenic variant, and/or has lack of disease association in case-control studies, and/or is located in a region inconsistent with a known cause of pathogenicity. -
RAF1-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at